Study identifies correlations between BioLight’s TeaRx diagnostic parameters and benchmark tests for dry eye syndrome
BioLight Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, today announced the completion of a U.S. clinical study, conducted by Ora, Inc. Andover, MA, designed to compare widely used benchmark tests for dry eye with its TeaRx diagnostic parameters that test components of tear film.